In addition to the scientific duties listed below, I was also an Operations Manager for the Kelly BPO program.• 15+ years of mammalian cell culture experience – lines include primary, cancer and immortalized.• Performed qPCR to screen clones for stable cell line generation.• Performed competitive binding assays (SPA) to screen compounds for the metabolic target.• Screened small molecules in cAMP and β-arrestin assays for a metabolic target.• Screened small molecules in a calcium mobilization assay for a metabolic target.• Optimized a FLIPR Ca assay for the CKD target and transferred method to Discovery Sciences.• Developed and executed insulin secretion assays to examine the effects of GRK2 inhibition on GLP-1 mediated insulin secretion in INS-1 832/13 cells.• Executed large molecule screens for three major Obesity programs simultaneously – 2 are transitioning to NME status.• Wrote macros replacing established data analysis templates which improved data analysis turn-a-round and data integrity.• Executed cAMP (HTMS & htrf), β-Arrestin and solubility assays in support of cardiovascular programs.• Executed high throughput screens for Cardiovascular and Neuroscience programs.• Optimized off-target profiling assays.• Performed off-target profiling of directed synthesis compounds using both cAMP (htrf) and calcium mobilization assays.• Re-optimized for higher throughput and executed a luciferase assay that utilized a transiently transfected HEK293 cell line to screen small molecules for the TNFα program.

This was a contract position for People 2.0 Global.• Developed and validated an Osteogenesis assay using a Mesenchymal Stem Cell Line.• Developed and validated a High-Content Screening assay using a Rhabdomyosarcoma Cell Line. • Established, maintained and banked 35 cancer cell lines for Cell Line Biomarker Discovery Project. • Provided statistical data analysis that included: Z*score, Z-Prime, -LOGp-value, %CV, standard deviation and median.• Lentivirus-Transduced Schnurri-3 in a Mesenchymal Stem Cell line for an Osteogenesis assay.• Executed primary and confirmatory screens of an annotated small-molecule library for CMAP projects. • Used MSD technology to show upregulation of IGFBP-1 by transfection with Let-7 miRNA.

• Promoted to Research Scientist II, 2003.• Investigated levels of KCNQ 1-5 in tissues and primary bladder smooth muscle cells by qRT-PCR.• Investigated levels of APJ receptor in H9c2 and HL-1 cell lines by qRT-PCR.• Extensive experience with mammalian cell culture and aseptic technique (10.5 years).• Showed activation of AKT and ERK1/2 signaling in APJ-over-expressing cardiomyocytes, suggesting a potential mechanism for cardioprotection ( SDS-PAGE and Western analysis).• Showed attenuation of IGF-induced p70S6 kinase phosphorylation and preservation of AKT phosphorylation status with the use of novel Rapamycin analogs (SDS-PAGE and Western analysis). • Screened a series of Rapalogs for their ability to induce autophagy (Western analysis).• Used ELISA for the determination of Apelin, uPA, tPA, and TGF-b1 in sera and cell culture preparations. • Developed and validated cAMP, IP-One, calcium efflux and ligand binding assays for Wyeth’s Apelin and Niacin programs, resulting in their advancement to a Discovery milestone ahead of established deadlines. • Developed and validated a membrane potential assay to identify compounds that hyperpolarize bladder smooth muscle cells (FLIPR). • Introduced technology and cell-based assays to a newly-formed heart failure group, which resulted in the accelerated advancement of Wyeth's Apelin program.• Created Excel spreadsheets to manage multi-assay data from compound-screening efforts.• Created procedures for all newly developed and validated assays for submission into corporate database.• Investigated GPCR-driven signal transduction in mammalian cell lines.• Showed inhibition of cardiac hypertrophy by Rapamycin and adenoviral-infected GDF-15 using immunocytochemistry.